Predictive power of Model for End-Stage Liver Disease and Child-Turcotte-Pugh score for mortality in cirrhotic patients

Abstract

Aim of the studyTo assess the performance of Child-Turcotte-Pugh (CTP) and Model for End-Stage Liver Disease (MELD) scores’ kinetics during hospitalization in predicting in-hospital mortality in patients with liver cirrhosis.Material and methodsOne hundred and seventy-four cases of hospitalized liver cirrhosis patients were selected. The diagnosis of cirrhosis was made based on clinical, biochemical, ultrasonic, histological, and endoscopic findings and results. CTP and MELD scores at admission and ΔCTP and ΔMELD were calculated. Univariate and multivariate logistic regression and receiver-operating characteristic (ROC) curve analysis were performed. In the models, odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. The area under the ROC curve (AUC) was used to measure the accuracy. For the optimal cutoff point, sensitivity (SE), specificity (SP), positive predictive value (PPV), and negative predictive value (NPV) were calculated. The Kaplan-Meier method was used to construct survival curves, and the log-rank test was used to compare time to death, with respect to MELD and CTP categories.ResultsAmong the assessed scores, the highest area under the ROC curve (AUC) in univariate logistic regression analysis was calculated for ΔMELD ≥ 1, followed by ΔCTP ≥ 1, CTP > 8, and MELD > 17. Based on the selected criteria, multivariate models were created that were characterized by an outstanding ability to predict the in-hospital mortality.ConclusionsIn-hospital mortality is relatively high in patients with liver cirrhosis. The combination of CTP and MELD scoring methods, combined with their kinetics, allows for the prediction of short-term mortality.

Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study

“…Another important finding is significant improvements in liver function and liver enzymes. Child–Pugh is considered a strong bedside prognostic indicator in advanced liver disease, often used with MELD to determine need and priority for transplant [ 18 ]. Here, the vast majority improved both scores or remained steady, which correlates with an increase in serum albumin, another clinical prognostic indicator.…”

“…All patients filled out the Euro-Qol Index survey, including the visual analog scale evaluation at baseline and at 12 m. We also incorporated the nonutility-based Short Form-36v2 survey, which provides a detailed profile of health-related quality of life [ 18 ].…”

Systematic review with meta‐analysis: Nutritional screening and assessment tools in cirrhosis

“…Importantly, malnutrition emerged as a robust predictor of pre‐transplant mortality in the majority of studies, an association with death found in 69% of evaluated NAT data points, with a RR for mortality ranging from 2.2 to 5.8. This evidence that 7 out of 10 times that it was evaluated, malnutrition was associated with pre‐transplant mortality, adds data to support the use of malnutrition as a potentially modifiable prognostic factor in patients with cirrhosis . The association of malnutrition with post‐transplant mortality was less clear, identified in only 28% of evaluated NAT data points, with a RR of death of 3.0 from the meta‐analysis.…”

“…This evidence that 7 out of 10 times that it was evaluated, malnutrition was associated with pre-transplant mortality, adds data to support the use of malnutrition as a potentially modifiable prognostic factor in patients with cirrhosis. 67 The association of malnutrition with post-transplant mortality was less clear, identified in only 28% of evaluated NAT data points, with a RR of death of 3.0 from the meta-analysis. Given the small number of studies evaluating non-mortality outcomes, it is challenging to draw definitive conclusions for the association of malnutrition with these measures.…”

The Effect of Modified Sini Decoction on Survival Rates of Patients with Hepatitis B Virus Related Acute-on-Chronic Liver Failure

“…The patients' clinical and laboratory data were collected: (1) the 12-week survival rate; (2) the Child-Turcotte Pugh (CTP) score [21] and model for endstage liver disease (MELD) score [22] before and after treatment for 4, 8, and 12 weeks; (3) biochemical indicator: serum ALT, AST, total bilirubin (TBIL), and albumin (ALB) at 0, 4, 8, and 12 weeks after treatment, respectively; all assays used a colorimetric method (Automatic Analyzer 7170A, Hitachi, Japan); (4) PTA was performed following the manufacturer's instructions (STA-evolution, STAGO, France). It was tested at 0, 4, 8, and 12 weeks after treatment, respectively.…”